July 25, 2016 10:56 AM ET

Pharmaceuticals

Company Overview of GlaxoSmithKline Pakistan Ltd.

Company Overview

GlaxoSmithKline Pakistan Limited manufactures and markets research based ethical specialties, other pharmaceutical, and consumer products in Pakistan and internationally. It operates through two segments, Pharmaceuticals and Consumer healthcare. The company deals in anti-infective, respiratory, vaccines, dermatological, gastrointestinal, analgesics, urology, central nervous system, allergy, cardiovascular, and vitamins therapy areas. It offers its pharmaceutical products primarily under the Augmentin, Seretide, Amoxil, Velosef, Zantac, and Calpol brands; consumer healthcare products under the Panadol, Horlicks, Sensodyne, and ENO brands; and vaccines under the Synflorix, Rotarix, Engerix-B, ...

35, Dockyard Road

West Wharf

Karachi,  74000

Pakistan

2,372 Employees

Phone:

92 21 111 475 725

Fax:

92 21 3231 4898

Key Executives for GlaxoSmithKline Pakistan Ltd.

GlaxoSmithKline Pakistan Ltd. does not have any Key Executives recorded.

GlaxoSmithKline Pakistan Ltd. Key Developments

GlaxoSmithKline Pakistan Ltd. Announces Board Changes

GlaxoSmithKline Pakistan Ltd. announced the casual vacancy due to resignation of Mr. Yahya Zakaria from the Board of Directors, it was decided by the members of the board to appoint the undersigned Syed Azeem Abbas Naqvi, as Non-Executive Director of GSK Pakistan Limited.

Glaxosmithkline Pakistan Ltd. Reports Earnings Results for the Quarter Ended March 31, 2016

GlaxoSmithKline Pakistan Ltd. reported earnings results for the quarter ended March 31, 2016. For the quarter, the company reported net sales of PKR 6,112.337 million compared to PKR 5,732.905 million a year ago. Operating profit was PKR 918.860 million compared to PKR 789.470 million a year ago. Profit before taxation was PKR 914.860 million compared to PKR 784.151 million a year ago. Profit after taxation from continuing operations was PKR 572.900 million or PKR 1.80 per share compared to PKR 475.498 million or PKR 1.50 per share a year ago. Total profit after taxation was PKR 697.188 million or PKR 2.19 per share compared to PKR 514.589 million or PKR 1.62 per share a year ago.

GlaxoSmithKline Pakistan Ltd., Board Meeting, Apr 27, 2016

GlaxoSmithKline Pakistan Ltd., Board Meeting, Apr 27, 2016. Agenda: To consider the financial results for the first quarter ended March 31, 2016.

Similar Private Companies By Industry

Company Name Region
3S Pharmaceuticals (Pvt) Ltd. Middle East/Africa
Biocef (Private) Limited Middle East/Africa
Biogenist Pharma (Pvt.) Limited Middle East/Africa
Herbion International, Inc. Middle East/Africa
Macter International Limited Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
Spin-Off/Split-Off
August 25, 2015
GlaxoSmithKline Consumer Healthcare Pakistan Limited
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact GlaxoSmithKline Pakistan Ltd., please visit www.gsk.com.pk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.